The 2254118-43-7, currently referred to as Mosunetuzumab, presents an exciting advance in cancer treatment field. It's an CD20 binding antibody-drug created for selective administration of cytotoxic substances directly https://nannieohub873142.wikiexpression.com/6372409/drug_2254118_43_7_the_novel_new_antibody_conjugate